Merck Signs an Exclusive License and Collaboration Agreement with Kelun-Biotech for Seven Antibody-drug Conjugate Candidates
Shots:
- Kelun-Biotech to receive $175M up front, equity investment, ~$9.3B in development, regulatory & sales milestones, if it does not retain China, Hong Kong & Macau rights for option ADCs & if all candidates achieve approval along with royalties on net sales for any commercialized ADC product
- Merck to get an exclusive global license to research, develop, manufacture & commercialize multiple preclinical ADC therapies & also obtain an exclusive option to obtain additional licenses for ADC candidates
- Kelun-Biotech retains the right to research, develop, manufacture & commercialize licensed and option ADCs for mainland China, Hong Kong, and Macau. The collaboration enables Merck to strengthen its portfolio and prioritize the development of multiple oncology candidates for cancers
Ref: Merck | Image: Merck
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
